How do I hire an interim CRO for a medtech company in 2027?

Signals you actually need this

Most founders reach for an interim revenue leader about two quarters after the evidence first appeared. The evidence is usually sitting in the CRM, unread. Before you post a role or call a network, pull four numbers from the last eighteen months: pipeline coverage against quota, average sales cycle by deal type, win rate by stage, and time-to-first-close for every rep you have hired. If you cannot produce those four numbers in under an hour, that itself is the first signal — you do not have a revenue engine, you have a set of relationships that happen to produce orders.

The clearest trigger is flat revenue with growing headcount. You added two reps and a clinical specialist, your burn went up by roughly $600K annualized, and bookings moved sideways. That is not a hiring problem, it is a system problem: territory design, comp plan, or qualification criteria. An interim CRO earns their fee in that scenario faster than anywhere else, because the fix is structural and a structural fix is exactly what a fractional operator is built to deliver inside ninety days.

The second trigger is the departure gap. Your VP of Sales resigned, your search for a permanent CRO will realistically take four to six months in medtech (the candidate pool is small, and the good ones are under non-solicits and unvested equity), and you have a quota year running whether or not anyone is steering. A bridge engagement here is not a compromise — it is often the better outcome, because the interim inherits no political debt and can make the personnel calls a permanent hire would spend a year avoiding.

The third trigger is channel confusion. Medtech companies routinely run direct reps, independent distributors, and clinical application specialists against the same accounts. When two of those three are compensated on the same order, you get channel conflict, and channel conflict shows up as unexplained discounting, stalled deals near close, and reps who quietly stop logging activity. Founders often misread this as a motivation problem. It is an architecture problem, and it is one of the few problems where a leader who has run indirect channels before is worth several multiples of a strong generalist.

A fourth, subtler signal: your forecast is wrong in the same direction every quarter. Consistent over-forecasting means your stage definitions are aspirational rather than evidence-based — a deal moves to "verbal" when a clinician likes the device, not when the capital request has a line item in a budget cycle. Consistent under-forecasting means your reps are sandbagging against an unrealistic quota. Both are fixable in a diagnostic engagement, and neither requires a full-time hire.

Then there is the RevOps signal, which is the one most medtech founders underweight. If nobody owns the definitions — what counts as a qualified opportunity, when a trial converts to a booking, how consumable revenue is attributed back to the capital placement that created it — then every dashboard you build sits on sand. An interim CRO with real RevOps discipline will often spend their first three weeks doing nothing but definition work, and founders sometimes read that as slow. It is not slow. It is the only sequence that works, because every subsequent decision about territory, comp, and forecast depends on those definitions holding.

Finally, the honest counter-signal. If your revenue problem is actually a product, regulatory, or reimbursement problem — no CPT code, a weak clinical dataset, a 510(k) pathway that keeps slipping — no revenue leader on earth fixes that. A good interim will tell you this in week two and refund the rest of the diagnostic. A bad one will sell you a comp plan redesign for a device hospitals cannot get paid to use.

What good looks like versus what bad looks like

The single most reliable predictor of a successful medtech interim engagement is what the person does in their first thirty days. A strong operator runs a revenue audit: CRM hygiene review, pipeline coverage math, rep activity data, and five to ten win/loss interviews conducted personally — not delegated to a survey tool. They come back with a written document, prioritized, with an explicit list of what they are *not* going to fix. A weak operator arrives with a playbook from their last company and starts installing it in week one. If your candidate proposes tactics before they have talked to a single lost customer, that is a red flag worth ending the trial over.

Good also looks like specificity under interview pressure. Do not accept "I've worked with healthcare companies." Ask: walk me through one capital equipment deal you personally closed — who signed, what committee approved it, what quarter of the hospital's fiscal year did it land in, and what nearly killed it. The answers you want to hear involve value analysis committees, capital budget timing, GPO or IDN contract eligibility, reimbursement pathways, and clinical evidence used as sales collateral. A candidate who has genuinely lived this will complain about specific things — the September budget freeze, the VAC that meets monthly and skipped a month, the surgeon champion who left for another system mid-cycle. Genuine experience produces genuine grievances.

Bad looks like a candidate who cannot name two medtech companies where they carried a number rather than advised. It also looks like someone who wants the title but not the pipeline reviews. Ask directly: are you willing to run a weekly deal inspection with my reps, on camera, for the duration? The ones who hesitate are consultants, and a consultant is a different purchase with a different price.

There is a structural comparison worth holding in your head throughout. A fractional CRO commits three to twelve months at 10–20 days monthly, costs a retainer plus possible equity, diagnoses in two to four weeks, and is genuinely easy to end. A full-time VP of Sales costs roughly $200K–$300K base plus variable, benefits, and equity, takes ninety-plus days to ramp, and carries real severance and culture risk if wrong. The interim must be pre-vetted for domain because there is no time to train; the full-time hire can be a strong generalist you develop. Neither is superior — they answer different questions. The interim answers "what is broken and what do we do." The permanent hire answers "who lives with the consequences for the next four years."

The adjacent lesson: this same good-versus-bad frame transfers almost intact to fractional CFO, fractional CMO, and interim RevOps leadership hires. The diagnostic-first pattern, the milestone-tied terms, the refusal of non-competes — all of it holds. What changes is only the domain vetting question. For a fractional CFO in medtech you would probe revenue recognition on capital-plus-consumable bundles instead of VAC navigation.

Real cost and ROI ranges

Price a fractional revenue leader on days, not on outcome promises. The market convention is a day rate multiplied by a committed monthly minimum, invoiced monthly in arrears, with a small first-month retainer to secure calendar. Ten days a month buys you diagnosis, weekly pipeline inspection, and comp or process redesign. Fifteen to twenty days a month buys you an actual operator — someone running the team, sitting in deals, and making personnel calls. Below ten days you are not buying leadership; you are buying advice, and you should call it what it is and pay advisory rates for it. Five days a month is a board-observer or deal-coach arrangement, and it will not change your numbers because nobody can hold a pipeline in their head on that cadence.

Equity shows up in maybe a third of these deals. The common shape is 0.25%–1.0% of fully diluted shares vesting over two years, traded against a materially lower cash rate. That trade favors the company when cash is tight and favors the operator when the company is genuinely close to an inflection. Be careful with the cliff: a one-year cliff on a six-month engagement is a fiction that will poison the exit conversation. Use monthly or quarterly vesting on interim grants, and put an acceleration-on-acquisition clause in only if you are actually in a process.

For ROI, the honest math is comparative rather than absolute. Set the counterfactual: what does six months of the status quo cost? If you have four reps at $180K fully loaded attaining 55% of a $1.2M quota each, the gap between current attainment and a realistic 75% is roughly $960K of bookings a year. An interim engagement at 15 days a month for six months costs a fraction of that gap. You do not need the engagement to be transformative — you need it to move attainment by a few points and to prevent one bad full-time hire. Preventing a single mis-hired VP of Sales, with recruiting fees, six months of salary, severance, and the lost year, is frequently the entire return by itself.

Budget the adjacent costs too, because founders forget them. Travel is real in medtech: hospital selling requires being in the building, and an interim covering three regions will bill or expense meaningful travel. CRM remediation may require a contractor or a RevOps analyst for six to eight weeks. Call-recording and coaching tooling, if you do not already have it, is a per-seat annual cost. Sales training or certification for a device launch has its own line. A tidy way to think about it: the interim's fee is roughly two-thirds of the true program cost, and the remaining third is the tooling and data work that makes their recommendations executable.

Watch for the two failure modes that destroy the ROI case. The first is scope drift into interim-CEO territory — the founder starts routing product, marketing, and partnership decisions through the interim because they are competent and present. That feels efficient and is actually how a six-month engagement becomes an eighteen-month dependency. The second is the unmeasured engagement. If you did not write down baseline pipeline coverage, win rate, and cycle length in week one, you will have no way to argue at month six about whether it worked, and you will renew or terminate on vibes.

Set three to five deliverables in the engagement letter and tie a slice of compensation to them. Good deliverables are verifiable: a completed and delivered revenue audit; documented stage definitions live in the CRM with reps trained on them; two reps hired and ramped to first close; a rebuilt comp plan approved by the board; call coaching in place with a defined weekly cadence. Bad deliverables are "increase revenue" and "improve culture." Termination should be thirty days' notice from either side, and payment should not be contingent on outcomes outside the operator's control — a device that fails to clear a regulatory milestone is not their miss.

How it plugs into your existing workflow

An interim CRO is a systems change, not a headcount addition, and the integration work determines whether anything survives their exit. Start with the reporting line: the interim reports to the CEO, full stop. Every rep, sales ops resource, and clinical specialist reports to the interim for the duration. Half-measures — where two senior reps keep dotted-lining to the founder — produce exactly the ambiguity that makes turnarounds fail.

Grant real system access on day one: CRM admin or near-admin, the marketing automation platform, call recordings, and read access to the financial model. A leader who has to ask for a report every time they want to test a hypothesis will test fewer hypotheses. This is where RevOps and the interim CRO become inseparable — if you have a RevOps person, they should be the interim's first and closest partner, and if you do not, the interim will need contractor budget to stand up the basics.

Then set the operating cadence and do not let it slip. Weekly deal inspection with the full team. Bi-weekly one-on-ones with each rep. Monthly business review with the CEO and, once a quarter, with the board. Every one of those meetings should have a written artifact — a pipeline snapshot, a coaching note, a board memo — because those artifacts are the handoff package. An engagement that produces no documents produces no institutional memory, and you will be re-buying the same diagnosis in eighteen months.

Plan the exit from the first week. Require documentation of the sales process, key account plans, rep scorecards, the forecast methodology, and a written handoff memo. Schedule a thirty-day overlap with the permanent leader if the timing allows — that overlap is worth paying for even at a premium day rate, because context transfer between two revenue leaders in person is a different quality of transfer than a document. When the term ends, end it. No ghost advising, no standing Friday call that persists for a year. An interim who lingers past the agreed date is usually evidence that the founder is avoiding a hiring decision, and that avoidance costs more than the retainer ever did.

Two adjacent workflow effects are worth anticipating. First, marketing will feel the change within a month: tighter qualification criteria almost always reduce the number of leads that count as opportunities, and if nobody has warned the demand-gen team, they will read a real improvement as a personal attack on their metrics. Get ahead of it with a shared definition of a qualified opportunity, signed by both sides. Second, finance will see forecast variance change shape — usually it gets worse for a quarter as sandbagged and inflated deals get re-staged honestly, then materially better. Tell your CFO and your board that this will happen, in advance and in writing, or the honest re-baselining will look like a miss.

On the contract itself: do not ask for a non-compete. Serious fractional operators run portfolios and will decline, and the ones who accept are usually the ones with no other work. Ask instead for a twelve-month non-solicit covering your employees, standard confidentiality, and a conflicts clause requiring disclosure of any directly competitive engagement. That combination protects what actually needs protecting without disqualifying the entire top tier of the market.

Related questions

How long should the paid trial project be?

Two weeks is the working standard — long enough for a real revenue audit, short enough that a bad fit costs you one invoice. Scope it to a written deliverable: findings, prioritized recommendations, and an explicit proposal for what a full engagement would cover.

Can an interim CRO carry a personal quota?

Yes, but scope it explicitly in writing. Player-coach arrangements typically assign 20–30% of the total target to the interim personally. Decide up front whether you are buying deal closure or system building — a leader chasing their own number coaches less.

What if we already have a RevOps analyst?

That is an advantage. Pair them directly with the interim in week one and protect their time. The analyst executes the data remediation the audit surfaces, which means the recommendations get built rather than filed, and the capability survives after the interim leaves.

Does this apply outside medtech?

The engagement structure transfers cleanly to diagnostics, dental, veterinary, and industrial equipment — anywhere long capital cycles meet a recurring consumable stream. Only the domain vetting questions change. Pure SaaS engagements move faster because the buying committee is smaller and cycles are shorter.

Should the board interview the candidate?

Have one board member or lead investor take a thirty-minute call, not a full panel. You want a second read on judgment and a stakeholder who will not be surprised by the spend — but keep the hiring decision with the CEO, since the interim reports to the CEO.

FAQ

What is the typical notice period for ending a fractional CRO engagement?

Thirty days' notice from either side is the common term. Some agreements permit immediate termination with payment in lieu of notice. Confirm it in writing before the first day, and make sure the notice clause is genuinely mutual — one-sided termination rights signal an operator who has been burned or one who plans to leave.

How do I verify a candidate's medtech claims?

Ask for specific company names and direct references from those engagements, then actually call them. Three questions do most of the work: what was the revenue situation when they started, what measurably changed, and would you hire them again. Cross-check the dates and titles against LinkedIn — vague overlaps and unexplained gaps are worth asking about directly.

Should I hire through a network or search on my own?

Networks and communities that concentrate senior revenue operators shorten the search and give you a soft reference layer. Your own network produces better-calibrated candidates when it produces any. Run both in parallel — the search takes weeks either way, and the marginal cost of a second channel is a few hours.

What if the diagnostic says my problem is not sales?

Take the finding and stop the engagement. A report concluding that your gap is reimbursement, clinical evidence, or product-market fit is the most valuable outcome the diagnostic can produce, because it saves you from spending a year and several hundred thousand dollars optimizing a funnel that was never the constraint.

Can an interim CRO hire and fire?

They should be able to, within limits you set in advance. Give them explicit authority to hire against an approved headcount plan and to manage out clear underperformers on a documented process with your HR partner in the loop. An interim with no personnel authority cannot fix a personnel problem, which is often the actual problem.

How do I keep the gains after they leave?

Insist on documentation as a deliverable rather than a courtesy, keep the operating cadence running with the CEO in the chair if there is a gap, and give the permanent hire a thirty-day overlap. Institutional memory lives in written artifacts and repeated meetings, not in one person's head.

Sources

• U.S. Food and Drug Administration — Medical Devices
• Centers for Medicare & Medicaid Services
• AdvaMed — Advanced Medical Technology Association
• Harvard Business Review
• First Round Review
• SaaStr
• Pavilion
• MedTech Dive

Related on PULSE

• How do I find a fractional CRO in Millsboro in 2027?
• How do I hire a fractional CRO in Tulsa in 2027?
• How do I find a fractional CRO in Oakton in 2027?
• Where do I find an interim CRO in Durham in 2027?
• How do I find a fractional CRO in Montgomery Village in 2027?
• How do I hire a fractional CRO in Charlotte in 2027?